Physician profile
Milton C Roach
NPI 1922005974
$12,476.85
in general payments reported to CMS, 2019-2025
54 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $1,399 · 2021: $1,828 · 2022: $1,990 · 2023: $2,034 · 2024: $2,081 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,965.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,808.65 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $1,443.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,245.17 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,186.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $933.58 | 2019-2025 | |
| Amgen INC. | $931.58 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $481.39 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $298.82 | 2022-2024 | Azstarys |
| Abbott Laboratories | $294.40 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $258.70 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $258.41 | 2019-2024 | Vaqta, Gardasil 9, Capvaxive |
| Axsome Therapeutics, INC. | $253.15 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $247.58 | 2019-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $231.52 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $202.55 | 2019-2025 | Zoryve |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.